These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 31208929)
1. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929 [TBL] [Abstract][Full Text] [Related]
2. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. Moreno-Cubero E; Larrubia JR World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882 [TBL] [Abstract][Full Text] [Related]
3. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma. Choi B; McBride A; Scott AJ Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928 [TBL] [Abstract][Full Text] [Related]
4. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985 [TBL] [Abstract][Full Text] [Related]
5. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. Brown ZJ; Heinrich B; Steinberg SM; Yu SJ; Greten TF J Immunother Cancer; 2017 Nov; 5(1):93. PubMed ID: 29157287 [TBL] [Abstract][Full Text] [Related]
6. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma. Yao X; Wang L; Gao J Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798 [TBL] [Abstract][Full Text] [Related]
7. Nivolumab for the treatment of hepatocellular carcinoma. Finkelmeier F; Waidmann O; Trojan J Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963 [TBL] [Abstract][Full Text] [Related]
9. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664 [TBL] [Abstract][Full Text] [Related]
10. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Bresnahan E; Lindblad KE; Ruiz de Galarreta M; Lujambio A Clin Cancer Res; 2020 Oct; 26(20):5276-5286. PubMed ID: 32327473 [TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441 [TBL] [Abstract][Full Text] [Related]
12. Oral chemotherapy for the treatment of hepatocellular carcinoma. Yamamoto S; Kondo S Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090 [TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives. Mazzolini GD; Malvicini M Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Noonan A; Pawlik TM Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579 [No Abstract] [Full Text] [Related]
15. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Tian M; Shi Y; Liu W; Fan J Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
18. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Moriguchi M; Umemura A; Itoh Y Clin J Gastroenterol; 2016 Aug; 9(4):184-90. PubMed ID: 27401471 [TBL] [Abstract][Full Text] [Related]
19. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? Remon J; Besse B; Soria JC BMC Med; 2017 Mar; 15(1):55. PubMed ID: 28285592 [TBL] [Abstract][Full Text] [Related]
20. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Barbee MS; Ogunniyi A; Horvat TZ; Dang TO Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]